Simple Summary Multiple myeloma, a cancer of the bone marrow, is the commonest cancer
of adults in the Western World. Therapies have advanced dramatically in recent years …

Although the approval of new drugs has improved the clinical outcome of multiple myeloma
(MM), it was widely regarded as incurable over the past decades. However, recent …

Tumor necrosis factor (TNF) receptor-2 (TNFR2) has attracted considerable interest as a
target for immunotherapy. Indeed, using oligomeric fusion proteins of single chain-encoded …

Multiple myeloma (MM) growth is supported by an immune-tolerant bone marrow
microenvironment. Here, we find that loss of Never in mitosis gene A (NIMA)-related kinase …

T-cell-engaging bispecific antibodies (T-BsAb) have produced impressive clinical responses
in patients with relapsed/refractory B-cell malignancies, although treatment failure remains a …

Positron emission tomography (PET) is an imaging modality used for the noninvasive
assessment of tumor staging and response to therapy. PET with 18F labeled …

B-acute lymphoblastic leukemia (B-ALL) is one of the most common pediatric cancers,
wherein regulatory T cells (Treg) and exhausted CD8+ T cells may be important in its …

Multiple myeloma is characterized by a wide clinical heterogeneity due to an intricate
network of interactions between bone marrow-resident clonal plasma cells and the …

Simple Summary Here, we describe the main interactions of multiple myeloma cells in the
bone marrow with non-hematological and hematological immune cells that impact the …

The chemokine CCL21 regulates immune and cancer cell migration through its receptor
CCR7. The Ccl21a gene encodes the isoform CCL21-Ser, predominantly expressed in the …